AI assistant
EXELIXIS, INC. — Director's Dealing 2017
May 17, 2017
30561_dirs_2017-05-16_c3647670-a731-40a9-8fb3-054756880511.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2017-05-15
Reporting Person: Schwab Gisela (Pres Prod Dev & Med Aff & CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-15 | Common Stock | M | 12501 | $5.04 | Acquired | 183005 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-15 | Option (right to buy) | $5.04 | M | 12501 | Disposed | 2018-12-15 | Common Stock (12501.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 14186 | Indirect |
Footnotes
F1: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2017.
F2: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F3: Represents 14,186 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 15, 2017.
F4: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012.